Skip to main content

Anwar Ahmed, MD

Anwar Ahmed, MD

Medical Director of Neurology

Neuroscience

Anwar Ahmed

Overview

Anwar Ahmed, MD, is a highly qualified neurologist and our Medical Director of Neurology whose special interests include movement disorders and tremor analysis in Parkinson’s disease and related neurodegenerative disorders, as well as dystonia. He joined our team in Central Florida from the Cleveland Clinic in Ohio, where he served in multiple leadership roles in the movement disorders and neurological restoration programs and the Huntington Disease Center of Excellence. A graduate of the esteemed Dow Medical College in Pakistan, he completed his neurology residency at Wayne State University’s hospitals in Michigan followed by a fellowship in surgical approaches to movement disorders and motor physiology at Columbia-Presbyterian University Medical Center in New York and a clinical research fellowship in movement disorders at the Cleveland Clinic. His research and published works have focused on such topics as unusual movement disorders, treatment of tremor caused by multiple sclerosis, brain stimulation for movement disorders, and Parkinson’s disease.

Education & Training

Education

Dow Medical College, University of Karachi, Pakistan

Residency

Neurology at Wayne State University School of Medicine

Board Certifications

American Board of Psychiatry and Neurology

Associated Clinical Trials

NCT05399888

Alzheimer Disease: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer’s Disease Dementia

Icon for trial | 247AD201 Alzheimer Disease: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of BIIB080 in Subjects with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer&rsqu

This study is currently enrolling.

Alzheimer’s Disease (AD): The purpose of this study is to look at whether BIIB080 (the study drug) can help people with Alzheimer’s Disease (AD), how safe it is, and how the body handles taking it (known as tolerability). Parti ...

NCT05526391

Takeda Development Center Americas, Inc. / “A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy”

Icon for trial | TAK-341-2001 Takeda Development Center Americas, Inc. / “A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Mul

This study is currently enrolling.

Multiple System Atrophy: The goals of this study are to find out the following: How effective is TAK-341 in treating people with MSA. Assess what TAK-341 does to the body (pharmacokinetics [PK]) and measure the amount of TAK-34 ...